It is one of the most understandable questions a person can ask — and one that reflects a very human wish for a simple, accessible answer to a frightening possibility. Will a blood test show lung cancer? The honest answer is that it depends on which blood test you mean. Routine blood tests cannot diagnose lung cancer directly — but they can reveal important clues that prompt further investigation. And in an exciting development for UK patients, a new generation of advanced blood testing technology is beginning to transform how lung cancer is detected and managed on the NHS.
Understanding what different blood tests can and cannot tell you — and what the right next steps are if you have concerns — puts you in the strongest possible position to act early and with clarity.
What Routine Blood Tests Can and Cannot Tell You
A standard blood test — the kind a GP might request when you present with breathlessness, fatigue, or a persistent cough — cannot diagnose lung cancer. There is no single routine blood marker that confirms the presence of lung cancer in a way that is reliable enough to replace imaging and tissue analysis. This is important to understand, both so you are not falsely reassured by a normal blood result and so you are not unnecessarily alarmed if your GP requests blood tests alongside other investigations.
That said, routine blood tests can be genuinely informative in the context of suspected lung cancer. The NHS recommends them as part of the initial assessment to rule out other explanations for symptoms and to flag abnormalities that may indicate the body is under significant physiological stress. A standard panel might reveal:
Anaemia
A low red blood cell count or reduced haemoglobin is common in people with cancer, including lung cancer. It can contribute to fatigue, breathlessness, and pallor — symptoms that may initially be attributed to other causes.
Elevated Inflammatory Markers
A raised C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) indicates significant inflammation in the body and, while non-specific, can be a flag that something beyond a simple infection is present.
Abnormal Liver Function Tests
If lung cancer has spread to the liver, liver function blood tests may reveal abnormalities — though these changes are not specific to cancer and can have many other causes.
Elevated Calcium
Some lung cancers — particularly squamous cell carcinoma — can cause hypercalcaemia (raised blood calcium) through the production of a parathyroid hormone-related protein. An elevated calcium level on a routine panel can be a meaningful prompt for further investigation.
Full Blood Count Abnormalities
Changes in white blood cell patterns, platelet counts, or other components of the full blood count can occasionally raise clinical suspicion that something more significant than infection is occurring.
Importantly, normal results on all of these markers do not rule out lung cancer. Many people with early-stage lung cancer have entirely normal routine blood results — which is precisely why symptoms, risk factors, and imaging are central to the diagnostic pathway, not blood tests alone.
What About Tumour Markers?
Tumour markers are proteins or other substances that certain cancers produce in higher quantities, which can be measured in the blood. In some cancers — such as prostate cancer (PSA) or ovarian cancer (CA-125) — tumour markers play a meaningful role in screening and monitoring. For lung cancer, however, the picture is considerably less clear-cut.
Several tumour markers have been studied in lung cancer — including CEA (carcinoembryonic antigen), CYFRA 21-1, NSE (neuron-specific enolase), and CA 19-9. While elevated levels of these markers can be associated with certain types of lung cancer, none of them is sensitive or specific enough to reliably diagnose lung cancer on its own. They can be raised in many other conditions, and they can be normal even in the presence of established lung cancer. Current UK clinical guidelines do not recommend tumour marker blood tests as a primary diagnostic tool for lung cancer.
Their greatest current value is in monitoring treatment response and detecting recurrence in people already diagnosed with specific lung cancer subtypes — not in initial detection.
The Exciting New Development: Liquid Biopsies and ctDNA Testing
This is where the picture becomes considerably more encouraging — and where UK patients are at the forefront of a genuine medical breakthrough.
Cancerous tumours shed fragments of their own DNA into the bloodstream. These fragments — known as circulating tumour DNA, or ctDNA — can be detected and analysed using a blood test called a liquid biopsy. In 2024, NHS England became the first health service in the world to introduce a blood-test-first approach to suspected lung cancer diagnosis, using ctDNA liquid biopsies. Up to 15,000 patients with suspected non-small cell lung cancer — the most common type, accounting for around 80 to 85% of cases — can now benefit from this test annually across NHS hospitals in England.
The ctDNA test identifies specific genetic mutations driving the tumour, allowing clinicians to match patients to targeted therapies rather than relying on standard chemotherapy. In NHS pilot data, patients who had liquid biopsy testing received their results needed for treatment decisions up to 16 days earlier than those going through the traditional tissue biopsy pathway alone — a clinically significant reduction in an anxious and critical waiting period.
The Royal Marsden NHS Foundation Trust, working with Guardant Health, has led much of this innovation through the Marsden360 service — a dedicated liquid biopsy testing facility that has already tested thousands of patients with suspected advanced lung cancer. An Oxford University Hospitals NHS Foundation Trust study is also investigating whether ctDNA-based protein biomarker analysis can detect lung cancer even before it is visible on a CT scan — a development that, if validated, could transform early detection entirely.
It is important to be clear about what liquid biopsies currently do and do not offer. At present, they are used in the NHS as an adjunct to — not a replacement for — CT scanning and tissue biopsy in patients with suspected lung cancer. They are not yet available as a general population screening tool. But they represent a significant step forward in what blood testing can contribute to lung cancer care, and the pace of development in this field is genuinely rapid.
What the NHS Diagnostic Pathway Actually Looks Like
For anyone presenting to a GP with symptoms that may indicate lung cancer — a persistent cough, unexplained weight loss, coughing up blood, breathlessness, chest pain, or hoarseness — the standard UK diagnostic pathway proceeds as follows:
- GP assessment and blood tests: A clinical consultation to assess symptoms and risk factors, alongside blood tests to rule out other explanations and flag relevant abnormalities.
- Chest X-ray: This is typically the first imaging investigation. As NHS guidance notes, most lung tumours appear as a white-grey mass on X-ray — though X-rays cannot give a definitive diagnosis and cannot distinguish cancer from other conditions such as a lung abscess.
- CT scan: A CT scan provides far more detailed images and is usually the next step after a chest X-ray. It can identify the size, location, and spread of any tumour, and assess whether nearby lymph nodes appear involved.
- Bronchoscopy or biopsy: Where imaging indicates a suspicious lesion, a tissue sample is taken — either via bronchoscopy (a camera passed into the airways) or a CT-guided needle biopsy — for analysis under a microscope to confirm the diagnosis and identify the cancer type.
- ctDNA liquid biopsy: For eligible patients with suspected non-small cell lung cancer, a ctDNA blood test is now offered alongside or before tissue biopsy to identify genetic mutations and guide targeted treatment decisions.
NICE recommends that anyone referred on a suspected cancer pathway should have a diagnosis — or a ruling out of cancer — within 28 days of referral. If you are concerned about waiting times or want to move more quickly through this process, a private GP consultation can facilitate faster access to imaging and specialist referral.
Symptoms That Should Prompt Urgent Assessment
If you are experiencing any of the following — particularly if you are over 40, smoke or have smoked, or have a family history of lung cancer — please seek a GP assessment promptly rather than waiting to see whether symptoms resolve:
- A new cough, or a change in a long-standing cough, lasting three weeks or more
- Coughing up blood, even a small amount
- Unexplained breathlessness that has developed or worsened
- Unexplained weight loss or loss of appetite
- Chest or shoulder pain that does not have an obvious musculoskeletal cause
- Persistent hoarseness or a change in voice quality
- Recurrent chest infections that do not resolve in the usual timeframe
- Unexplained fatigue or feeling generally unwell for several weeks
At The Private GP in Birmingham, we offer same-day appointments with GMC-registered doctors who take persistent and unexplained symptoms seriously. A face-to-face GP consultation gives you a thorough clinical assessment, with same-day blood testing and prompt referral for imaging where indicated. If you are worried, the worst thing you can do is wait. Book an appointment today and get the clarity you deserve.
What a Private Blood Test Can Offer Right Now
While no blood test can definitively diagnose or rule out lung cancer on its own, a comprehensive private blood panel can provide genuinely useful clinical information in the context of persistent or unexplained symptoms. At The Private GP, our private blood testing service in Birmingham can assess markers including a full blood count, inflammatory markers, liver function, calcium levels, and more — giving you and your doctor a detailed picture of what your body is signalling, quickly and without the wait.
Equally important is the clinical context those results are interpreted in. A blood test result means most when it is reviewed by a doctor who understands your symptoms, your history, and your risk factors — and who can act on it appropriately. That is precisely what our consultations are designed to provide. If imaging is needed, we can arrange a CT or MRI referral promptly, ensuring you are not left waiting for answers.
Frequently Asked Questions
- Can a full blood count detect lung cancer?
A full blood count (FBC) cannot diagnose lung cancer, but it can reveal abnormalities that prompt further investigation — including anaemia, changes in white blood cell patterns, or elevated platelet counts that can sometimes be associated with malignancy. A normal FBC result does not rule out lung cancer, particularly at an early stage. If you have persistent symptoms, imaging and a clinical assessment are essential regardless of blood test results.
- What blood tests are done when lung cancer is suspected?
According to NHS guidance, initial blood tests for suspected lung cancer typically include a full blood count, liver function tests, calcium, and U&E (urea and electrolytes). These help rule out other conditions, identify any organ involvement, and flag metabolic abnormalities associated with some cancers. Where lung cancer is confirmed, ctDNA liquid biopsy testing is now available on the NHS for eligible patients with suspected non-small cell lung cancer to guide targeted treatment decisions.
- What is a liquid biopsy and can I access one privately?
A liquid biopsy is a blood test that detects circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. It can identify specific genetic mutations driving a tumour and help guide targeted treatment. On the NHS, ctDNA testing is currently available for patients with suspected non-small cell lung cancer as part of the diagnostic pathway. Private availability varies — if you would like to discuss whether this type of testing is appropriate for your circumstances, a private GP consultation can help clarify your options.
- How quickly can lung cancer be diagnosed in the UK?
NICE guidelines recommend that anyone referred on a suspected cancer pathway receives a diagnosis or ruling out of cancer within 28 days of referral. NHS England’s introduction of ctDNA liquid biopsy testing has reduced the time to treatment decisions for lung cancer patients by up to 16 days in pilot data, by running blood analysis alongside or before tissue biopsy. If you are concerned about waiting times on the NHS, a private GP can facilitate faster access to chest imaging and specialist referral.
- Should I see a GP if I am worried about lung cancer?
Yes — and you should do so promptly rather than monitoring symptoms yourself. Lung cancer is most treatable when identified early, and the symptoms that warrant assessment — a persistent new cough, breathlessness, unexplained weight loss, or coughing up blood — should never simply be waited upon. At The Private GP in Birmingham, same-day appointments are available with no lengthy waiting times. A private blood test and clinical consultation can provide a clear starting point, with onward referral arranged promptly where needed.